Strategies to block TNF-α activity, seeking to neutralize its inflammatory role, have met some success in the treatment of epithelial cancers, and to a lesser extent also in subsets of patients with primary MDS, although with varying degrees of therapeutic benefit [15]–[17], [40]. The gene discussed is TNF; the disease is myelodysplastic syndrome.